Identification of Novel Malaria Transmission-Blocking Vaccine Candidates

Control measures have significantly reduced malaria morbidity and mortality in the last two decades; however, the downward trends have stalled and have become complicated by the emergence of COVID-19. Significant efforts have been made to develop malaria vaccines, but currently only the RTS,S/AS01 v...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Eizo Takashima, Mayumi Tachibana, Masayuki Morita, Hikaru Nagaoka, Bernard N. Kanoi, Takafumi Tsuboi
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	immuno-profiling malaria Plasmodium reverse vaccinology transmission-blocking vaccine (TBV) wheat germ cell-free system (WGCFS) Microbiology QR1-502
Acceso en línea:	https://doaj.org/article/b63bc3e9818d45f1932166a67844f8bc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b63bc3e9818d45f1932166a67844f8bc
record_format	dspace
spelling	oai:doaj.org-article:b63bc3e9818d45f1932166a67844f8bc2021-12-01T19:48:11ZIdentification of Novel Malaria Transmission-Blocking Vaccine Candidates2235-298810.3389/fcimb.2021.805482https://doaj.org/article/b63bc3e9818d45f1932166a67844f8bc2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fcimb.2021.805482/fullhttps://doaj.org/toc/2235-2988Control measures have significantly reduced malaria morbidity and mortality in the last two decades; however, the downward trends have stalled and have become complicated by the emergence of COVID-19. Significant efforts have been made to develop malaria vaccines, but currently only the RTS,S/AS01 vaccine against Plasmodium falciparum has been recommended by the WHO, for widespread use among children in sub-Saharan Africa. The efficacy of RTS,S/AS01 is modest, and therefore the development of more efficacious vaccines is still needed. In addition, the development of transmission-blocking vaccines (TBVs) to reduce the parasite transmission from humans to mosquitoes is required toward the goal of malaria elimination. Few TBVs have reached clinical development, and challenges include low immunogenicity or high reactogenicity in humans. Therefore, novel approaches to accelerate TBV research and development are urgently needed, especially novel TBV candidate discovery. In this mini review we summarize the progress in TBV research and development, novel TBV candidate discovery, and discuss how to accelerate novel TBV candidate discovery.Eizo TakashimaMayumi TachibanaMasayuki MoritaHikaru NagaokaBernard N. KanoiTakafumi TsuboiFrontiers Media S.A.articleimmuno-profilingmalariaPlasmodiumreverse vaccinologytransmission-blocking vaccine (TBV)wheat germ cell-free system (WGCFS)MicrobiologyQR1-502ENFrontiers in Cellular and Infection Microbiology, Vol 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	immuno-profiling malaria Plasmodium reverse vaccinology transmission-blocking vaccine (TBV) wheat germ cell-free system (WGCFS) Microbiology QR1-502
spellingShingle	immuno-profiling malaria Plasmodium reverse vaccinology transmission-blocking vaccine (TBV) wheat germ cell-free system (WGCFS) Microbiology QR1-502 Eizo Takashima Mayumi Tachibana Masayuki Morita Hikaru Nagaoka Bernard N. Kanoi Takafumi Tsuboi Identification of Novel Malaria Transmission-Blocking Vaccine Candidates
description	Control measures have significantly reduced malaria morbidity and mortality in the last two decades; however, the downward trends have stalled and have become complicated by the emergence of COVID-19. Significant efforts have been made to develop malaria vaccines, but currently only the RTS,S/AS01 vaccine against Plasmodium falciparum has been recommended by the WHO, for widespread use among children in sub-Saharan Africa. The efficacy of RTS,S/AS01 is modest, and therefore the development of more efficacious vaccines is still needed. In addition, the development of transmission-blocking vaccines (TBVs) to reduce the parasite transmission from humans to mosquitoes is required toward the goal of malaria elimination. Few TBVs have reached clinical development, and challenges include low immunogenicity or high reactogenicity in humans. Therefore, novel approaches to accelerate TBV research and development are urgently needed, especially novel TBV candidate discovery. In this mini review we summarize the progress in TBV research and development, novel TBV candidate discovery, and discuss how to accelerate novel TBV candidate discovery.
format	article
author	Eizo Takashima Mayumi Tachibana Masayuki Morita Hikaru Nagaoka Bernard N. Kanoi Takafumi Tsuboi
author_facet	Eizo Takashima Mayumi Tachibana Masayuki Morita Hikaru Nagaoka Bernard N. Kanoi Takafumi Tsuboi
author_sort	Eizo Takashima
title	Identification of Novel Malaria Transmission-Blocking Vaccine Candidates
title_short	Identification of Novel Malaria Transmission-Blocking Vaccine Candidates
title_full	Identification of Novel Malaria Transmission-Blocking Vaccine Candidates
title_fullStr	Identification of Novel Malaria Transmission-Blocking Vaccine Candidates
title_full_unstemmed	Identification of Novel Malaria Transmission-Blocking Vaccine Candidates
title_sort	identification of novel malaria transmission-blocking vaccine candidates
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/b63bc3e9818d45f1932166a67844f8bc
work_keys_str_mv	AT eizotakashima identificationofnovelmalariatransmissionblockingvaccinecandidates AT mayumitachibana identificationofnovelmalariatransmissionblockingvaccinecandidates AT masayukimorita identificationofnovelmalariatransmissionblockingvaccinecandidates AT hikarunagaoka identificationofnovelmalariatransmissionblockingvaccinecandidates AT bernardnkanoi identificationofnovelmalariatransmissionblockingvaccinecandidates AT takafumitsuboi identificationofnovelmalariatransmissionblockingvaccinecandidates
_version_	1718404591990603776

Identification of Novel Malaria Transmission-Blocking Vaccine Candidates

Ejemplares similares